I, for one, have had enough of the weak performance and weak leadership of IMGN. Shareholders must rise up and make it clear to the BOD that Junius must perform early in 2014, or go. IMGN has the technology, they don't have strong and competent business, or advanced drug development leadership. This must change NOW. 20+ years of no returns for the shareholders is Not Acceptable! If Junius were coaching a college, or pro sports team, he would have been replaced years ago. Why do biotech BOD's allow incompetent management to continue? It's an industry-wide problem that must be fixed. There are very few business-savvy biotech CEO's and numerous weak, failed leaders that continue to squander capital and opportunity while earning large pay packages.